Derma Sciences to Present at the Rodman & Renshaw Annual Global Investment Conference

PRINCETON, N.J., May 11 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (Nasdaq:  DSCI), a medical device and pharmaceutical company focused on advanced wound care, will present at the Rodman & Renshaw Annual Global Investment Conference. The Conference will take place May 16 – 18, 2010 at the Grosvenor House Hotel in London, UK.

Edward J. Quilty, Chairman and CEO of Derma Sciences will present on Tuesday, May 18, 2010 at 10:40 am BST (5:40 am ET) in the Spencer Suite. Additional information regarding the conference can be found at http://rodm.com/conferences?id=44.

The presentation will be webcast live and may be accessed at http://www.wsw.com/webcast/rrshq17/dsci.ob or on the Company's website at http://www.dermasciences.com.

To access a live audio webcast or the subsequent archived recording, log on to http://www.wsw.com/webcast/rrshq17/dsci.ob or the Company's website at http://www.dermasciences.com.  Please connect several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

A replay will be available on both sites for ninety days.

About Derma Sciences, Inc.

Derma Sciences is a global medical device and pharmaceutical company focused on wound care.  Its key product, MEDIHONEY®, is the leading brand of honey-based dressings for the management of wounds and burns.  The product has been shown to be effective in a variety of indications, and was the focus of a positive large-scale randomized controlled trial on leg ulcers.  Other key novel products introduced into the $14 billion global wound care market include XTRASORB™ for better management of wound exudates, and BIOGUARD™ for infection prevention.  Derma also has in development DSC127, a novel pharmaceutical for accelerated wound healing and scar reduction.  DSC127, an angiotensin analog, has shown positive healing results in multiple pre-clinical animal models.  One possible mode of action of the drug is the up-regulation of mesenchymal stem cells at the wound site.  Derma expects to announce the key efficacy endpoint results from this study by the end of 2010.

For more information about Derma Sciences, Inc., visit http://www.dermasciences.com.

Forward-Looking Statements

Statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements which may be made in this release or which are otherwise made by or on behalf of the Company. Factors which may affect the Company's results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include but are not limited to, those discussed in the Company's fillings with the Securities and Exchange Commission.

SOURCE Derma Sciences, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED